L2HGDH
Basic information
Region (hg38): 14:50237563-50312229
Previous symbols: [ "C14orf160" ]
Links
Phenotypes
GenCC
Source:
- L-2-hydroxyglutaric aciduria (Definitive), mode of inheritance: AR
- L-2-hydroxyglutaric aciduria (Definitive), mode of inheritance: AR
- L-2-hydroxyglutaric aciduria (Strong), mode of inheritance: AR
- L-2-hydroxyglutaric aciduria (Supportive), mode of inheritance: AR
- mitochondrial disease (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
L-2-hydroxyglutaric aciduria | AR | Biochemical; Oncologic | A low lysine diet has been reported as resulting in clinical and biochemical improvement; An increased risk of cerebral neoplasms has been reported, and awareness may lead to early detection and treatment | Biochemical; Neurologic; Oncologic | 6787330; 1642474; 7609438; 7609437; 9860123; 10399870; 15548604; 15385440; 15824270; 18931888; 21937992; 22241392; 22353300; 22459673 |
ClinVar
This is a list of variants' phenotypes submitted to
- L-2-hydroxyglutaric_aciduria (233 variants)
- Inborn_genetic_diseases (61 variants)
- not_provided (37 variants)
- not_specified (24 variants)
- L2HGDH-related_disorder (9 variants)
- Abnormality_of_metabolism/homeostasis (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the L2HGDH gene is commonly pathogenic or not. These statistics are base on transcript: NM_000024884.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 50 | 55 | ||||
missense | 123 | 12 | 149 | |||
nonsense | 9 | |||||
start loss | 1 | 1 | ||||
frameshift | 10 | |||||
splice donor/acceptor (+/-2bp) | 12 | |||||
Total | 26 | 16 | 129 | 62 | 3 |
Highest pathogenic variant AF is 0.0000359916
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
L2HGDH | protein_coding | protein_coding | ENST00000267436 | 10 | 74986 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0000422 | 0.992 | 125708 | 0 | 40 | 125748 | 0.000159 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.425 | 235 | 254 | 0.925 | 0.0000124 | 2972 |
Missense in Polyphen | 97 | 108.8 | 0.89156 | 1340 | ||
Synonymous | 0.705 | 80 | 88.4 | 0.905 | 0.00000401 | 935 |
Loss of Function | 2.34 | 11 | 23.1 | 0.475 | 0.00000129 | 272 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000383 | 0.000383 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000326 | 0.000326 |
Finnish | 0.0000924 | 0.0000924 |
European (Non-Finnish) | 0.000150 | 0.000149 |
Middle Eastern | 0.000326 | 0.000326 |
South Asian | 0.000131 | 0.000131 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Pathway
- Butanoate metabolism - Homo sapiens (human);The oncogenic action of L-2-hydroxyglutarate in Hydroxygluaricaciduria;The oncogenic action of D-2-hydroxyglutarate in Hydroxygluaricaciduria ;Interconversion of 2-oxoglutarate and 2-hydroxyglutarate;Pyruvate metabolism and Citric Acid (TCA) cycle;The citric acid (TCA) cycle and respiratory electron transport;Metabolism;Urea cycle and metabolism of arginine, proline, glutamate, aspartate and asparagine
(Consensus)
Recessive Scores
- pRec
- 0.159
Intolerance Scores
- loftool
- 0.360
- rvis_EVS
- 0.02
- rvis_percentile_EVS
- 55.45
Haploinsufficiency Scores
- pHI
- 0.391
- hipred
- N
- hipred_score
- 0.465
- ghis
- 0.557
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.750
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- L2hgdh
- Phenotype
- behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- 2-oxoglutarate metabolic process;cellular protein metabolic process;oxidation-reduction process
- Cellular component
- mitochondrion;mitochondrial inner membrane;integral component of membrane;integral component of mitochondrial inner membrane
- Molecular function
- (S)-2-hydroxy-acid oxidase activity;2-hydroxyglutarate dehydrogenase activity